Perrigo Company plc Form 8-K Summary
Business Context and Reporting Period
Perrigo Company plc (PRGO), an Ireland-based pharmaceutical company, filed this Current Report on February 27, 2020. The filing announces the release of earnings results for the fourth quarter and full year ended December 31, 2019. The detailed financial data is contained in the attached press release (Exhibit 99.1), which is not included in the text of this 8-K.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. It serves as a notification of the earnings release and defines the methodology for non-GAAP financial measures used by management.
Management utilizes non-GAAP measures to evaluate ongoing operating trends, excluding items such as:
- Amortization of acquired intangible assets
- Restructuring and separation charges
- Acquisition and integration costs
- Impairment charges and litigation costs
- Foreign currency translation movements
Material Changes and Adjustments
The filing details specific adjustments made to reported results to derive non-GAAP figures for the periods ended December 31, 2019, and 2018:
- Ranitidine Market Withdrawal: For 2019, adjustments were made for the impact of the ranitidine market withdrawal, including the reversal of returns and inventory writedowns. Management views this as an industry-wide event not reflective of underlying operating performance.
- Divestitures: Adjustments exclude operating results attributable to the infant foods product line and the animal health business to focus on the continuing business.
- Other Items: Adjustments include changes in financial assets, gains/losses on investment securities, and milestone income related to royalty rights (2018).
Outlook, Risks, and Management Commentary
Management states that non-GAAP measures are useful for comparing performance against competitors and assessing future prospects. Regarding risks, the company notes that product recalls occur from time to time in the industry and may recur in the future. However, they emphasize that the ranitidine recall was an industry-wide action and that the company continues to manufacture and sell other products treating the same conditions.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific revenue, net income, and EPS figures for Q4 and FY 2019.
- Verify the reconciliation between GAAP and non-GAAP financial measures to understand the magnitude of excluded items.
- Assess the specific financial impact of the ranitidine market withdrawal reversal on 2019 profitability.
- Confirm the status of the divested infant foods and animal health businesses.
- Check for any updated forward-looking guidance provided in the attached press release.